ReviewCytokine & growth factor reviews2021
Macrophage-derived cytokines in pneumonia: Linking cellular immunology and genetics.
Review in Cytokine & growth factor reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- Self-Assembled Carrier-Free Nanostructures of Anemoside B4 and Oleanolic Acid Alleviate Intestinal Injury Induced by IntraperitonealAntioxidants (Basel, Switzerland) · 2026Article
- Folate-mediated inflammatory microenvironment-responsive nanocarriers for the delivery of Moringa A to target NLRP3 for the treatment of viral pneumonia.International journal of pharmaceutics: X · 2026Article
- Genetic Regulation of Monocyte MicroRNAs and Their Implication in Musculoskeletal Diseases: A Cross-Ancestry Expression Quantitative Trait Loci and Imputation Study.International journal of molecular sciences · 2026Article
- Recurrent episodes of pneumonia are associated with worse lung function in people with HIV.PloS one · 2026Article
- Comparative immunogenicity and protective efficacy of BECC438 and BECC470 adjuvants in a vaccine formulation againstFrontiers in immunology · 2026Article
- Chick early amniotic fluid attenuates lipopolysaccharide-induced acute lung injury.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025Article
- Histopathological changes and inflammatory and cell death pathways in the lungs of Balb/c mice with pneumonia induced by different concentrations ofAnatomy & cell biology · 2025Article
- Biomimetic magnetobacterial microrobots for active pneumonia therapy.Nature communications · 2025Article
- Article
- Targeted Restoration of T-Cell Subsets by a Fluorinated Piperazine Derivative β-Cyclodextrin Complex in Experimental Pulmonary Inflammation.Molecules (Basel, Switzerland) · 2025Article
- Role of Inflammatory Markers as a Risk Factor for Community-Acquired Pneumonia Management.Medicina (Kaunas, Lithuania) · 2025Article
- Review
- Kaempferol MitigatesPharmaceuticals (Basel, Switzerland) · 2025Article
- Adenoviral Pneumonia Outbreak in Immunocompetent Adults-A Missed Antimicrobial Stewardship Opportunity?Antibiotics (Basel, Switzerland) · 2025Article
- Medicinal Plant-Derived Exosome-Like Nanovesicles as Regulatory Mediators in Microenvironment for Disease Treatment.International journal of nanomedicine · 2025Review
- Local and systemic cytokine profiles in children with pneumonia-associated lung consolidation.Frontiers in immunology · 2025Article
- Article
- Efficacy and safety of carrimycin in ten patients with severe pneumonia following solid organ transplantation.World journal of clinical cases · 2024Article
- A living neutrophil Biorobot synergistically blocks multifaceted inflammatory pathways in macrophages to effectively neutralize cytokine storm.Chemical science · 2024Article
- Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases.Respiratory research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophages represent the first line of anti-pathogen defense - they encounter invading pathogens to perform the phagocytic activity, to deliver the plethora of pro- and anti-inflammatory cytokines, and to shape the tissue microenvironment. Throughout pneumonia course, alveolar macrophages and infiltrated blood monocytes produce increasing cytokine amounts, which activates the antiviral/antibacterial immunity but can also provoke the risk of the so-called cytokine "storm" and normal tissue damage. Subsequently, the question of how the cytokine spectrum is shaped and balanced in the pneumonia context remains a hot topic in medical immunology, particularly in the COVID19 pandemic era. The diversity in cytokine profiles, involved in pneumonia pathogenesis, is determined by the variations in cytokine-receptor interactions, which may lead to severe cytokine storm and functional decline of particular tissues and organs, for example, cardiovascular and respiratory systems. Cytokines and their receptors form unique profiles in individual patients, depending on the (a) microenvironmental context (comorbidities and associated treatment), (b) lung monocyte heterogeneity, and (c) genetic variations. These multidisciplinary strategies can be proactively considered beforehand and during the pneumonia course and potentially allow the new age of personalized immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.